IMMUNITYBIO, INC. License Costs (Deprecated 2018-01-31)
IMMUNITYBIO, INC. (IBRX) reported License Costs (Deprecated 2018-01-31) of $500.00 thousand for the 1-month period ending 2018-01-31, per its 10-Q filed 2018-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LicenseCosts · last filed 2018-05-07
- 2018-01-31: License Costs (Deprecated 2018-01-31) 1 month $500.00K.
| Period end | License Costs (Deprecated 2018-01-31) 1 month |
|---|---|
| 2018-01-31 | $500.00K 10-Q · filed 2018-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |